Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma

  • Authors:
    • Nobukazu Fujimoto
    • Kenichi Gemba
    • Michiko Asano
    • Sae Wada
    • Katsuichiro Ono
    • Shinji Ozaki
    • Takumi Kishimoto
  • View Affiliations

  • Published online on: March 1, 2010     https://doi.org/10.3892/etm_00000048
  • Pages: 313-317
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive neoplasm primarily arising from surface serosal cells of the pleura and is strongly associated with asbestos exposure. Patients with MPM often develop pleural fluid as initial presentation. However, cytological diagnosis using pleural fluid is usually difficult and has limited utility. A useful molecular marker for differential diagnosis particularly with lung cancer (LC) is urgently needed. The aim of the present study was to investigate the diagnostic value of soluble mesothelin-related protein (SMRP) in pleural fluid. Pleural fluids were collected from 23 patients with MPM, 38 with LC, 26 with benign asbestos pleurisy (BAP), 5 with tuberculosis pleurisy (TP) and 4 with chronic heart failure (CHF), and the SMRP concentration was determined. All data were analyzed by using non-parametric two-sided statistical tests. The median concentration of SMRP in MPM, LC, BAP, TP and CHF were 11.5 (range 0.90-82.80), 5.20 (0.05-36.40), 6.65 (1.45-11.25), 3.20 (1.65-6.50) and 2.03 (1.35-2.80) nmol/l, respectively. The SMRP concentration was significantly higher in MPM than in the other diseases (P=0.001). The area under the ROC curve (AUC) values of the MPM diagnosis was 0.75 for the differential diagnosis from the other groups. Based on the cut-off value of 8 nmol/l, the sensitivity and specificity for diagnosis of MPM were 70.0 and 68.4%, respectively. These results indicate that the SMRP concentration in pleural fluid is a useful marker for the diagnosis of MPM.
View Figures
View References

Related Articles

Journal Cover

March-April 2010
Volume 1 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fujimoto N, Gemba K, Asano M, Wada S, Ono K, Ozaki S and Kishimoto T: Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma . Exp Ther Med 1: 313-317, 2010.
APA
Fujimoto, N., Gemba, K., Asano, M., Wada, S., Ono, K., Ozaki, S., & Kishimoto, T. (2010). Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma . Experimental and Therapeutic Medicine, 1, 313-317. https://doi.org/10.3892/etm_00000048
MLA
Fujimoto, N., Gemba, K., Asano, M., Wada, S., Ono, K., Ozaki, S., Kishimoto, T."Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma ". Experimental and Therapeutic Medicine 1.2 (2010): 313-317.
Chicago
Fujimoto, N., Gemba, K., Asano, M., Wada, S., Ono, K., Ozaki, S., Kishimoto, T."Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma ". Experimental and Therapeutic Medicine 1, no. 2 (2010): 313-317. https://doi.org/10.3892/etm_00000048